OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs. This recognition demonstrates OXB’s excellence in quality, innov ...